Humanized antibodies that recognize β-amyloid peptide

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7700751
APP PUB NO 20070238154A1
SERIAL NO

11707639

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
JANSSEN ALZHEIMER IMMUNOTHERAPYMADISON, NJ47
WYETH LLCMADISON, NJ300

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Basi, Guriq Palo Alto, US 17 715
Saldanha, Jose William Enfield, GB 28 719
Schenk, Dale B Burlingame, US 127 4391

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (4)
5227159 Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies 34 1992
2002/0009,445 Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease 101 2001
2002/0197,258 Compositions and methods for preventing protein aggregation in neurodegenerative diseases 90 2002
2004/0247,612 Immunogenic peptide composition for the prevention and treatment of Alzheimer's Disease 30 2004
 
Athena Neurosciences (1)
5766846 Methods of screening for compounds which inhibit soluble .beta.-amyloid peptide production 145 1993
 
RAMOT AT TEL-AVIV UNIVERSITY LTD. (2)
5688651 Prevention of protein aggregation 106 1994
2005/0152,878 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases 24 2005
 
SYNTEX, INCORPORATED (1)
5208036 N-(.omega., (.omega.-1)-dialkyloxy)- and N-(.omega., (.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor 147 1990
 
GLAXOSMITHKLINE LLC (3)
5817626 Modulators of beta-amyloid peptide aggregation 81 1995
5854215 Modulators of .beta.-amyloid peptide aggregation 67 1995
5854204 A.beta. peptides that modulate .beta.-amyloid aggregation 114 1996
 
WISCONSIN ALUMNI RESEARCH FOUNDATION (1)
6022859 Inhibitors of .beta.-amyloid toxicity 35 1997
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (2)
6165745 Recombinant production of immunoglobulin-like domains in prokaryotic cells 203 1994
6277375 Immunoglobulin-like domains with increased half-lives 290 1997
 
The United States of America as represented by the Department of Health and Human Services (5)
4912206 CDNA clone encoding brain amyloid of alzheimer's disease 41 1987
5472693 Family of anti-carcinoembryonic antigen chimeric antibodies 37 1993
5733548 Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments 34 1995
2003/0068,316 Anti-ADDL antibodies and uses thereof 83 2002
2003/0166,557 SEMA3B inhibits tumor growth and induces apoptosis in cancer cells 24 2002
 
ELI LILLY AND COMPANY (9)
5441870 Methods for monitoring cellular processing of .beta.-amyloid precursor protein 149 1992
5612486 Transgenic animals harboring APP allele having swedish mutation 142 1993
6114133 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreq.41) 106 1994
5624937 Chemical compounds as inhibitors of amyloid beta protein production 86 1995
5593846 Methods for the detection of soluble .beta.-amyloid peptide 220 1995
5605811 Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein 92 1995
5721130 Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of .beta.APP 108 1995
5837672 Methods and compositions for the detection of soluble .beta.-amyloid peptide 110 1995
6284221 Method for identifying .beta.-amyloid peptide production inhibitors 84 1996
 
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (1)
2003/0147,882 METHODS FOR AMYLOID REMOVAL USING ANTI-AMYLOID ANTIBODIES 56 1999
 
NEURALAB LIMITED (1)
2005/0123,544 Prevention and treatment of amyloidogenic disease 42 2004
 
SB2, INC. (2)
5624821 Antibodies with altered effector functions 473 1995
5648260 DNA encoding antibodies with altered effector functions 396 1995
 
DMS PHARMACEUTICAL INC. (1)
5231170 Antibodies to dense microspheres 88 1990
 
BIOSITE INCORPORATED (1)
6057098 Polyvalent display libraries 142 1997
 
RASO, VICTOR (3)
6582945 Immunological control of .beta.-amyloid levels in vivo 68 2000
2002/0136,718 Immunological control of beta-amyloid levels in vivo 64 2001
2005/0147,613 Immunological control of beta-amyloid levels in vivo 40 2005
 
ELAN PHARMACEUTICALS, INC. (1)
6610493 Screening compounds for the ability to alter the production of amyloid-.beta. peptide 46 1996
 
CREATIVE BIOMOLECULES, INC. (1)
5258498 Polypeptide linkers for production of biosynthetic proteins 320 1992
 
SCIOS NOVA INC. (3)
5220013 DNA sequence useful for the detection of Alzheimer's disease 79 1989
5187153 Methods of treatment using Alzheimer's amyloid polypeptide derivatives 82 1990
5387742 Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease 196 1991
 
MERCK SHARP & DOHME CORP. (1)
5358708 Stabilization of protein formulations 86 1993
 
SUN HEALTH CORPORATION, INC. (1)
5192753 Anti-rheumatoid arthritic drugs in the treatment of dementia 91 1991
 
PROTHENA BIOSCIENCES LIMITED (1)
6923964 Active immunization of AScr for prion disorders 36 2000
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (5)
4666829 Polypeptide marker for Alzheimer's disease and its use for diagnosis 283 1985
5270165 Method of diagnosis of amyloidoses 80 1991
5464823 Mammalian antibiotic peptides 68 1993
5750361 Formation and use of prion protein (PRP) complexes 68 1995
6175057 Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy 37 1997
 
Milkhaus Laboratory, Inc. (4)
5753624 Materials and methods for treatment of plaquing disease 90 1996
5798102 Treatment of cardiomyopathy 28 1997
5851996 Materials and methods for treatment of plaquing diseases 95 1998
6294171 Methods for treating disease states comprising administration of low levels of antibodies 81 2001
 
AUTOIMMUNE, INC. (4)
5849298 Treatment of multiple sclerosis by oral administration of bovine myelin 52 1993
5869054 Treatment of multiple sclerosis by oral administration of autoantigens 57 1995
5733547 Treatment of autoimmune arthritis by oral administration of type I or type III collagen 55 1995
5641473 Treatment of autoimmune diseases by aerosol administration of autoantigens 55 1995
 
UNIVERSITY OF IOWA RESEARCH FOUNDATION (1)
6339068 Vectors and methods for immunization or therapeutic protocols 206 1998
 
CELLTECH THERAPEUTICS LIMITED (1)
5677425 Recombinant antibody 124 1994
 
THE UNIVERSITY OF BRITISH COLUMBIA (1)
2006/0234,912 Methods for modulating neuronal responses 18 2006
 
MEMORIAL SLOAN-KETTERING CANCER CENTER (1)
6933368 Increasing antibody affinity by altering glycosylation of immunoglobulin variable region 81 2002
 
UNIVERSITY OF WASHINGTON (1)
5958883 Animal models of human amyloidoses 80 1995
 
CELLTECH LIMITED (1)
4816397 Multichain polypeptides or proteins and processes for their production 700 1984
 
NEW YORK BLOOD CENTER, INC. (1)
5620844 Assays for detecting hepatitis B virus envelope antigens or antibodies thereto and diagnostic test kits for use in performing the assays 23 1993
 
UNIVERSITY OF KANSAS (1)
5278049 Recombinant molecule encoding human protease nexin 43 1987
 
BRITISH TECHNOLOGY GROUP LIMITED (1)
5096706 Antigen-based treatment for adiposity 28 1986
 
ABBOTT BIOTHERAPEUTICS CORP. (1)
* 6210671 Humanized antibodies reactive with L-selectin 66 1995
 
Genentech, Inc. (13)
4816567 Recombinant immunoglobin preparations 2225 1983
5245015 Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro 38 1991
5866129 Method of producing an antibody with a peptide corresponding to membrane-bound IgA 35 1991
6407213 Method for making humanized antibodies 317 1993
5869046 Altered polypeptides with increased half-life 139 1995
6121022 Altered polypeptides with increased half-life 168 1995
6054297 Humanized antibodies and methods for making them 383 1995
5702906 Antibodies to neurotrophic factor-4 (NT-4) 30 1995
6267958 Protein formulation 235 1996
6194551 Polypeptide variants 278 1999
6528624 Polypeptide variants 211 1999
6538124 Polypeptide variants 177 2000
6639055 Method for making humanized antibodies 125 2000
 
THE OHIO STATE UNIVERSITY (1)
4713366 Antigenic modification of polypeptides 77 1985
 
IMMUNITOR COMPANY LTD. (1)
2003/0092,145 Viral vaccine composition, process, and methods of use 40 2001
 
ABBVIE BIOTHERAPEUTICS INC. (1)
5622701 Cross-reacting monoclonal antibodies specific for E- and P-selectin 65 1994
 
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (1)
5262332 Diagnostic method for Alzheimer's disease: examination of non-neural tissue 69 1989
 
INNOGENETICS N.V. (1)
2004/0265,919 Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease 51 2004
 
BAYER PHARMACEUTICALS CORPORATION (1)
5786180 Monoclonal antibody 369.2B specific for .beta. A4 peptide 83 1995
 
EPIMMUNE INC. (1)
5736142 Alteration of immune response using pan DR-binding peptides 84 1994
 
T C U.S.A. INC. (1)
6787129 Castor polyester as gloss agents in anionic systems 19 2003
 
BIOCLONES (PTY) LIMITED (1)
6261569 Retro-, inverso- and retro-inverso synthetic peptide analogues 66 1997
 
PROTEIN DESIGN LABS, INC. (5)
* 5530101 Humanized immunoglobulins 1163 1990
5585089 Humanized immunoglobulins 1236 1995
5693761 Polynucleotides encoding improved humanized immunoglobulins 549 1995
5693762 Humanized immunoglobulins 967 1995
6180370 Humanized immunoglobulins and methods of making the same 657 1995
 
UCB PHARMA S.A. (2)
2005/0123,534 Humanised antibodies 26 2004
2005/0136,054 Humanised antibodies 24 2004
 
MEDICAL RESEARCH COUNCIL (1)
5225539 Recombinant altered antibodies and methods of making altered antibodies 859 1991
 
CYTRX CORPORATION (1)
5824322 Compositions and methods for growth promotion 58 1996
 
ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (1)
5994083 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable 27 1995
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (3)
5837473 Methods of screening for agents affecting the deposition of .beta.-amyloid peptides on amyloid plaques in human tissue 54 1995
5877399 Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease 122 1996
6262335 Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 57 1998
 
CEDARS-SINAI MEDICAL CENTER (1)
5679348 Immunotherapy for recurrent HSV infections 53 1992
 
CELLTECH R&D LIMITED (2)
5859205 Humanised antibodies 486 1994
6632927 Humanized antibodies 262 2001
 
WYETH (2)
2006/0099,206 Methods and compositions for improving recombinant protein production 25 2005
2006/0210,557 Stabilized liquid polypeptide formulations 34 2006
 
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (1)
2006/0182,321 Method and apparatus for extracting third ventricle information 22 2004
 
NATIONAL RESEARCH COUNCIL OF CANADA (1)
5773007 Vaccine compositions 35 1994
 
NIHON UNIVERSITY (1)
6962984 IgA nephropathy-related DNA 25 2000
 
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (1)
5589154 Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease 83 1994
 
BTG INTERNATIONAL LIMITED (1)
6548640 Altered antibodies 138 1995
 
WYETH LLC (24)
7189819 Humanized antibodies that recognize beta amyloid peptide 50 2001
2005/0009,150 Humanized antibodies that recognize beta amyloid peptide 24 2002
7179892 Humanized antibodies that recognize beta amyloid peptide 74 2003
7256273 Humanized antibodies that recognize beta amyloid peptide 62 2003
2004/0171,815 Humanized antibodies that recognize beta amyloid peptide 38 2003
2004/0171,816 Humanized antibodies that recognize beta amyloid peptide 32 2003
2006/0188,512 Active immunization to generate antibodies to solble a-beta 22 2004
2004/0213,800 Active immunization to generate antibodies to soluble A-beta 42 2004
2005/0249,725 Humanized antibodies that recognize beta amyloid peptide 45 2004
2005/0118,651 Humanized antibodies that recognize beta amyloid peptide 50 2004
2007/0161,088 Beta immunogenic peptide carrier conjugates and methods of producing same 30 2004
2006/0160,161 Methods for assessing antibodies to neurodegenerative disease-associated antigens 41 2005
2006/0153,772 Contextual fear conditioning for predicting immunotherapeutic efficacy 24 2005
2006/0165,682 Humanized antibodies that recognize beta amyloid peptide 37 2005
2006/0198,851 Humanized Abeta antibodies for use in improving cognition 46 2005
2006/0240,486 Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies 31 2005
2006/0257,396 Abeta antibodies for use in improving cognition 41 2005
2006/0193,850 Anti a beta antibody formulation 50 2006
2006/0280,743 Humanized antibodies that recognize beta amyloid peptide 32 2006
2007/0082,367 Methods of purifying anti a beta antibodies 26 2006
2008/0050,367 Humanized antibodies that recognize beta amyloid peptide 26 2006
2007/0238,154 Humanized antibodies that recognize beta-amyloid peptide 24 2007
2008/0145,373 A-BETA IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME 34 2007
2009/0142,270 PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY 22 2008
 
LILLY AND COMPANY (1)
2004/0241,164 Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass 59 2004
 
NOVARTIS AG (1)
2004/0197,324 High concentration antibody and protein formulations 97 2004
 
WYETH HOLDINGS CORPORATION (2)
5723130 Adjuvants for vaccines against respiratory syncytial virus 46 1996
6399314 Methods of detection of amyloidogenic proteins 55 1999
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (2)
5750349 Antibodies to .beta.-amyloids or their derivatives and use thereof 151 1994
5955317 Antibodies to .beta.-amyloids or their derivatives and use thereof 99 1997
 
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (2)
5585100 Dual carrier immunogenic construct 78 1995
5955079 Dual carrier immunogenic construct 67 1995
 
INTELLECT NEUROSCIENCES INC. (1)
2003/0073,655 Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof 91 2002
 
BRONSON NUTRITIONALS, LLC (5)
5869093 Treatment of immune diseases by oral administration of autoantigens 66 1994
5645820 Treatment of autoimmune diseases by aerosol administration of autoantigens 63 1995
5571499 Treatment of autoimmune diseases by aerosol administration of autoantigens 81 1995
5571500 Treatment of autoimmune diseases through administration by inhalation of autoantigens 64 1995
5641474 Prevention of autoimmune diseases by aerosol administration of autoantigens 61 1995
 
Mindset Biopharmaceuticals (USA) (1)
2002/0086,847 Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof 89 2001
 
JANSSEN SCIENCES IRELAND UC (2)
6913745 Passive immunization of Alzheimer's disease 70 2000
2009/0069,544 HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE 17 2007
 
T CELL SCIENCES, INC. (1)
6284533 Plasmid-based vaccine for treating atherosclerosis 49 1998
 
PRAECIS PHARMACEUTICALS INCORPORATED (3)
6303567 Modulators of .beta.-amyloid peptide aggregation comprising D-amino acids 87 1996
5985242 Modulators of .beta.-amyloid peptide aggregation comprising D-amino acids 64 1997
2002/0133,001 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease 48 2001
 
ABBOTT LABORATORIES (1)
6015662 Reagents for use as calibrators and controls 41 1996
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (48)
6787523 Prevention and treatment of amyloidogenic disease 81 1998
6761888 Passive immunization treatment of Alzheimer's disease 100 2000
6710226 Transgenic mouse assay to determine the effect of A.beta. antibodies and A.beta. Fragments on alzheimer's disease characteristics 66 2000
6743427 Prevention and treatment of amyloidogenic disease 125 2000
6750324 Humanized and chimeric N-terminal amyloid beta-antibodies 82 2000
6787138 Prevention and treatment of amyloidogenic disease 71 2000
6787139 Prevention and treatment of amyloidogenic disease 69 2000
6787140 Prevention and treatment of amyloidogenic disease 68 2000
6787143 Prevention and treatment of amyloidogenic disease 58 2000
6787144 Prevention and treatment of amyloidogenic disease 70 2000
6787637 N-Terminal amyloid-.beta. antibodies 86 2000
6875434 Methods of treatment of Alzheimer's disease 70 2000
6890535 Pharmaceutical compositions and methods for treatment of amyloid diseases 49 2000
6905686 Active immunization for treatment of alzheimer's disease 61 2000
2004/0081,657 Prevention and treatment of amyloidogenic disease 51 2003
2005/0059,802 Prevention and treatment of amyloidogenic disease 44 2004
2004/0265,308 Prevention and treatment of amyloidogenic disease 51 2004
6808712 Prevention and treatment of amyloidogenic disease 36 2004
6818218 Prevention and treatment of amyloidogenic disease 39 2004
6866849 Prevention and treatment of amyloidogenic disease 70 2004
6866850 Prevention and treatment of amyloidogenic disease 66 2004
6982084 Prevention and treatment of amyloidogenic disease 42 2004
7014855 Prevention and treatment of amyloidogenic disease 58 2004
2005/0019,328 Prevention and treatment of amyloidogenic disease 49 2004
2005/0059,591 Prevention and treatment of amyloidogenic disease 42 2004
2004/0219,146 Prevention and treatment of amyloidogenic disease 34 2004
6962707 Prevention and treatment of amyloidogenic disease 46 2004
2004/0247,591 Prevention and treatment of amyloidogenic disease 23 2004
2004/0265,301 Prevention and treatment of amyloidogenic disease 29 2004
2005/0158,304 Prevention and treatment of amyloidogenic disease 26 2004
2004/0247,590 Prevention and treatment of amyloidogenic disease 27 2004
2005/0013,815 Prevention and treatment of amyloidogenic disease 43 2004
2005/0019,330 Prevention and treatment of amyloidogenic disease 68 2004
2005/0048,049 Prevention and treatment of amyloidogenic disease 51 2004
2005/0191,292 Prevention and treatment of amyloidogenic disease 26 2004
2005/0249,727 Prevention and treatment of amyloidogenic disease 43 2004
2005/0196,399 Prevention and treatment of amyloidogenic disease 27 2004
6946135 Prevention and treatment of amyloidogenic disease 44 2004
6972127 Prevention and treatment of amyloidogenic disease 65 2004
2005/0163,788 Prevention and treatment of amyloidogenic disease 41 2004
2005/0255,122 Prevention and treatment of amyloidogenic disease 41 2004
2007/0134,762 Immunogenic peptide carrier conjugates and methods of producing same 30 2004
2005/0142,132 Prevention and treatment of amyloidogenic disease 45 2005
2005/0191,314 Prevention and treatment of amyloidogenic disease 37 2005
2006/0029,611 Prevention and treatment of amyloidogenic disease 39 2005
2006/0034,858 Prevention and treatment of amyloidogenic disease 39 2005
2007/0154,480 Humanized antibodies that recognize beta amyloid peptide 29 2006
2008/0096,818 PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE 40 2007
 
AMERSHAM PLC (1)
2003/0135,035 Human ZZAP1 protein 25 2002
 
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
6417178 Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits 79 1997
 
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (1)
5858981 Method of inhibiting phagocytosis 45 1996
 
BAYER CORPORATION (1)
2002/0160,394 Regulation of transthyretin to treat obesity 62 2002
 
GENETICS INSTITUTE, LLC (5)
5385887 Formulations for delivery of osteogenic proteins 200 1993
6270757 Formulations for IL-11 28 1994
6372716 Formulations for factor IX 27 1994
5770700 Liquid factor IX formulations 53 1996
5744132 Formulations for IL-12 42 1997
 
Andrulis Pharmaceuticals Corp. (1)
5434170 Method for treating neurocognitive disorders 98 1993
 
XOMA TECHNOLOGY LTD. (2)
5618920 Modular assembly of antibody genes, antibodies prepared thereby and use 191 1994
5576184 Production of chimeric mouse-human antibodies with specificity to human tumor antigens 136 1994
 
UNIVERSITY OF SASKATCHEWAN (1)
5837268 GnRH-leukotoxin chimeras 32 1996
 
ANTIGENICS INC. (2)
5057540 Saponin adjuvant 228 1990
5583112 Saponin-antigen conjugates and the use thereof 93 1992
 
ZOETIS SERVICES LLC (1)
5989566 Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation 55 1996
 
The Scripps Research Institute (3)
4879213 Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse 208 1986
5846533 Antibodies specific for native PrP.sup.Sc 79 1996
6562341 Antibodies specific for native PrPSc 36 2001
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2)
4883666 Controlled drug delivery system for treatment of neural disorders 240 1987
5891991 Amyloid precursor-like protein and uses thereof 37 1996
 
HUNTINGTON POTTER (1)
5780587 Compounds and methods for inhibiting .beta.-protein filament formation and neurotoxicity 81 1995
 
UNIVERSITY OF ROCHESTER (1)
5231000 Antibodies to A4 amyloid peptide 136 1991
 
MCW RESEARCH FOUNDATION, INC. (1)
6057367 Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses 87 1997
 
ALTEON, INC. (1)
5935927 Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts 79 1996
 
MORPHOSYS AG (1)
2005/0169,925 Anti-amyloid beta antibodies and their use 55 2005
 
WASHINGTON UNIVERSITY (1)
7195761 Humanized antibodies that sequester abeta peptide 90 2002
 
CITY OF HOPE (2)
5652334 Method for design of substances that enhance memory and improve the quality of life 31 1993
5470951 Peptides for antagonizing the effects of amyloid .beta.protein 45 1993
 
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (1)
6150091 Direct molecular diagnosis of Friedreich ataxia 54 1996
 
PARDRIDGE, WILLIAM (1)
5004697 Cationized antibodies for delivery through the blood-brain barrier 103 1987
 
NEW YORK UNIVERSITY (2)
6713450 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits 52 2001
2003/0166,558 Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or polyglutamine repeats for induction of an immune response thereto 57 2002
 
Morphosys Gesellschaft fur Proteinoptimerung mbH (1)
5514548 Method for in vivo selection of ligand-binding proteins 99 1994
 
MILLENNIUM PHARMACEUTICALS, INC. (1)
6727349 Recombinant anti-CCR2 antibodies and methods of use therefor 29 2000
 
THE GENERAL HOSPITAL CORPORATION (1)
2003/0009,104 In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease 17 2001
 
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (1)
5744368 Methods for the detection of soluble amyloid .beta.-protein (.beta.AP) or soluble transthyretin (TTR) 66 1993
 
NEUROCHEM (INTERNATIONAL) LIMITED (2)
6331440 Peptide binding the KLVFF-sequence of amyloid-.beta. 39 1998
2002/0094,335 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases 82 2001
 
AMGEN INC. (1)
5731284 Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product 42 1995
 
SMITHKLINE BEECHAM CORPORATION (1)
6936698 Monoclonal antibodies with reduced immunogenicity 53 2001
 
SMITHKLINE BEECHAM BIOLOGICALS S.A. (1)
5776468 Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A 89 1996
 
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (1)
5601827 Diphtheria toxin vaccines 39 1995
 
UNIVERSITY OF SOUTHERN CALIFORNIA (1)
6218506 Amyloid .beta. protein (globular assembly and uses thereof) 99 1997
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
LONZA BIOLOGICS PLC (2)
* 9290563 Variant immunoglobulins with improved manufacturability 0 2015
* 2015/0104,449 Variant Immunoglobulins with Improved Manufacturability 0 2015
 
WYETH LLC (1)
8440799 Methods of purifying anti A β antibodies 0 2010
 
UNIVERSITAT ZURICH (3)
8906367 Method of providing disease-specific binding molecules and targets 1 2008
* 2010/0202,968 Method of Providing Disease-Specific Binding Molecules and Targets 1 2008
9580493 Anti-α synuclein binding molecules 0 2012
 
NATIONAL CHENG KUNG UNIVERSITY (2)
* 8597647 Humanized anti-IL-20 antibody and uses thereof 4 2012
9217031 Humanized anti-IL-20 antibody and uses thereof 1 2013
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 20, 2017
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 20, 2021
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00